New combo aims to turn Chemo-Resistant breast cancer curable
NCT ID NCT07457359
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for people with triple-negative breast cancer whose tumors don't shrink after standard chemotherapy. Participants receive targeted radiation to the tumor followed by immunotherapy (toripalimab) plus more chemo. The goal is to see if this combination can eliminate all cancer before surgery, allowing more patients to have breast-conserving surgery instead of mastectomy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Department of Radiation Oncology，the Second Affiliated Hospital of Zhejiang University School of Medicine, hangzhou, zhejiang
RECRUITINGHangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers